Acetylon Pharmaceuticals Announces Preclinical Data of ACY-1215 for the Treatment of Lymphoma Highlighted at 12th International Conference on Malignant Lymphoma (ICML)
6/20/2013 9:07:50 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals Inc., the leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that collaborators from Columbia University Medical Center presented an oral presentation on preclinical data of selective histone deacetylase (HDAC) 6 inhibitor, ACY-1215, in combination with bortezomib (Velcade®, Takeda Millennium Pharmaceuticals) for the treatment of lymphoma at the 12th International Conference on Malignant Lymphoma (ICML), on June 19, 2013, in Lugano, Switzerland. First author Jennifer E. Amengual, M.D., of Columbia University Medical Center presented the study, “Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor, ACY-1215 (ACY), and bortezomib (Bor), demonstrates synergistic antitumor activity in preclinical models of lymphoma.”
Help employers find you! Check out all the jobs and post your resume.